Business Information
The group's principal activity is to undertake the research and development of novel biopharmaceutical protein-based products for the treatment of human disease from its collection of proprietary genes discovered using its high-throughput signature-by-hybridization platform and from genes licensed-in from partners. It is researching several product candidates to treat various serious diseases and medical conditions. These product candidates target several markets, including cardiovascular disease and oncology. The group intends to develop and commercialize these product candidates on its own or in collaboration with other biotechnology or pharmaceutical companies. The group has two segments: nuvelo, which develops and plans to market therapeutic drugs for the treatment of human diseases, and callida, which develops and plans to commercialize the group's sequencing-by-hybridization (sbh) technology. On 31-Jan-2003, the group acquired variagenics, inc.
|
|
Name |
Title
|
Email
|
| Barry Zubrow | Vice Chmn. | N/A | | George Rathmann | Chmn. Emeritus | N/A | | Ted Love | Chmn., CEO | N/A | | Lee Bendekgey | Sr. VP, CFO, General Counsel | N/A | | Brian Kersten | VP - Regulatory Affairs, Quality Assurance, Analytical Sciences | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 3,888 | (130,553) | | 2005 | 545 | (71,611) | | 2004 | 195 | (52,489)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
